Bracco Diagnostics Inc. Receives Innovative Technology Designation from Vizient for LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension for Contrast Echocardiography
First Approval by U.S. Food and Drug Administration for Contrast Enhanced Ultrasonography of the Liver Received by Bracco Diagnostics Inc. for LUMASON ® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use
Click here to learn about the TRUTH1 Study.
Reference 1. Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Zižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study). AJNR Am J Neuroradiol. 2014 Oct 9. [Epub ahead of print]